Carole Faig
Director/Board Member bij CUE HEALTH INC.
Vermogen: 197 859 $ op 31-03-2024
Profiel
Carole T.
Faig is an Independent Director at Henry Schein, Inc. and Cue Health, Inc. She is also a Director at QuVa Pharma, Inc. and an Independent Director at Affinia Therapeutics, Inc. Previously, she worked as a Partner at Ernst & Young LLP.
She received her undergraduate degree from Sam Houston State University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
HENRY SCHEIN, INC.
0.00% | 04-03-2024 | 2 604 ( 0.00% ) | 196 654 $ | 31-03-2024 |
CUE HEALTH INC.
0.00% | 05-06-2023 | 6 376 ( 0.00% ) | 1 205 $ | 31-03-2024 |
Actieve functies van Carole Faig
Bedrijven | Functie | Begin |
---|---|---|
CUE HEALTH INC. | Director/Board Member | 01-01-2021 |
HENRY SCHEIN, INC. | Director/Board Member | 18-12-2023 |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Director/Board Member | 01-09-2021 |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | Director/Board Member | - |
Eerdere bekende functies van Carole Faig
Bedrijven | Functie | Einde |
---|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Opleiding van Carole Faig
Sam Houston State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
HENRY SCHEIN, INC. | Distribution Services |
CUE HEALTH INC. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
QuVa Pharma, Inc.
QuVa Pharma, Inc. Pharmaceuticals: MajorHealth Technology QuVa Pharma, Inc. provides sterile compounding pharmacy services. It develops, manufactures and distributes compounded sterile preparations. The firm provides vital compounded medications for obstetrics, OR, anesthesia, general medicine, cardiovascular, ER, and pain management. The company was founded by Stuart Hinchen and Peter Linsay Jenkins in 2015 and is headquartered in Austin, TX. | Health Technology |